“a favorable trend”

The physical and vitality scores of the 36-item short-form (SF-36) showed a favorable trend in the exercise group compared with the control group.

While there was no statistically significant difference in freedom from any atrial arrhythmia after a single procedure in the overall per-protocol population (HR, 0.81; 95% CI, 0.56–1.19), a favorable trend emerged after one or two procedures (HR, 0.62; 95% CI, 0.38–1.01) [ 17 ].

When all four highly heterogeneous studies were excluded, the OR adjusted to 18.70 (95% CI: 14.77–23.40; p = 0.16), indicating reduced precision but still suggesting a favorable trend toward renal benefit with TAF.

The analysis showed a difference in treatment effect between participants with and without previous MI, with a favorable trend for the effect in TM vs.

Therefore, while the current findings support a favorable trend for PD-1/PD-L1 inhibitors over docetaxel, the presence of bias may attenuate the strength of the evidence, particularly with respect to the magnitude of OS benefit.

19.7 months; HR 0.80; p = 0.018) and a favorable trend in OS (54.3 vs. 48.3 months) compared to those receiving the NACT-first sequence [ 17 ].

Subgroup analysis showed a favorable trend for DVMP in high-risk patients (HR 0.78), though this did not reach statistical significance.

When fixing R = 0.95, a favorable trend is a reduction in V with increasing repetitions, reflecting improved precision at a constant success probability.

The administration of anamorelin as a second-line or earlier treatment resulted in significant appetite improvement and BW gain at 3 weeks, with a favorable trend also observed in appetite improvement and BW gain at 12 weeks.

Treatment was shown to be associated with increased fecal SCFA production, improved immunonutritional parameters, as indicated by increased peripheral lymphocyte counts and prealbumin, and a favorable trend in growth.

The results revealed that compared to docetaxel, enzalutamide sequential therapy (HR: 0.22, 95% CI: 0.03–1.67) and enzalutamide combined therapy (HR: 0.46, 95% CI: 0.06–3.07) exhibited a favorable trend in enhancing the time to PSA progression in mHSPC patients ( Supplementary Material 6R ).

Although no statistically significant overall survival benefit was observed—likely due to limited statistical power—a favorable trend in OS was noted in the combination arm, supporting its clinical relevance [ 86 ].

Network Meta-Analysis In terms of overall survival, the forest plot illustrates that IC + RT&MTT (HR .68, 95% CrI 0.25-1.8), IC + CRT&MTT (HR .72, 95% CrI 0.071-7.4), and MTT-CRT (HR .93, 95% CrI 0.80-1.1) show a favorable trend over CRT.

While some studies have reported an increased rate of infection in older patients, others have observed a favorable trend with increasing age.

Notably, the pregnancy outcomes showed a favorable trend in the early hysteroscopy group, but there were no statistically significant differences.

The addition of pembrolizumab was associated with a favorable trend toward improved event-free survival versus placebo plus CRT, but the difference did not reach statistical significance in the ITT population (the 24-month event-free survival rate was 63.2% for the pembrolizumab arm versus 56.2% in the placebo arm). 62 Currently, several clinical trials are exploring the role of different ICIs in LACC setting ( Table 1 ).

Regarding computational load, although the decrease is more minor (91.8%–89.1%), a favorable trend remains, which is relevant given the intensive nature of these nodes.

22 , 23 A previous study has demonstrated a favorable trend in reducing TC and non-HDL-C from 1999 to 2011 in Tehran; however, it was limited due to the small sample size and single-district sampling. 24 Since then, no other study has evaluated the prevalence of dyslipidemia in Tehran, and its current net prevalence remains unknown.

In our cohort, objective postoperative BCVA at 3 months was better after EEA, and visual field indices showed a favorable trend.

Additionally, an exploratory study involving hepatocellular carcinoma patients treated with sorafenib showed a favorable trend in the prophylactic use of topical steroids compared to the non-application group; however, no statistically significant difference was observed [ 14 ], and its effectiveness has not been demonstrated.

Concerning APACHE II scores, our results suggest a favorable trend in mortality reduction with prolonged infusion in critically ill patients, irrespective of an APACHE II score above or below 20, differing from Roberts’ meta-analysis findings [ 38 ].

In the CT cohort, subgroup analysis indicated a favorable trend of DFS for patients with KRAS / NRAS / BRAF mutations and receiving up to four cycles of conversion therapy ( P _interaction, 0.005 and 0.013, respectively).

While BCI users showed a favorable trend, the effect was not statistically robust, and interpretation is limited by sample size.

With respect to ACM, LBBAP was associated with reduced mortality (RR: 0.74), mixed CSP showed a favorable trend (RR: 0.80), and LVSP was associated with significantly increased mortality (RR: 4.00).

Although the percentages were lower, a favorable trend for full-time and part-time employment was observed for women [ 40 ].